Tetrahydroaminoacridine is primarily studied for its potential application in the treatment of Alzheimer's disease. It acts as an acetylcholinesterase inhibitor, which helps to increase the levels of acetylcholine in the brain. This can improve cognitive function and memory in patients with Alzheimer's by enhancing communication between nerve cells. Additionally, it has been explored for its neuroprotective properties, which may help to slow the progression of neurodegenerative disorders. Research has also investigated its potential use in other conditions involving cognitive decline, though its efficacy and safety are still under study.